These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35633047)

  • 1. Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.
    Ohyama M; Matsudo K; Fujita T
    J Dermatol; 2022 Oct; 49(10):939-947. PubMed ID: 35633047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
    Cedirian S; Bruni F; Quadrelli F; Caro G; Fortuna M; Rossi A; Piraccini BM; Starace M
    J Cosmet Dermatol; 2023 Dec; 22(12):3347-3351. PubMed ID: 37415302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alopecia in patients with COVID-19: A systematic review and meta-analysis.
    Nguyen B; Tosti A
    JAAD Int; 2022 Jun; 7():67-77. PubMed ID: 35224518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience.
    Rizzetto G; Diotallevi F; Campanati A; Radi G; Bianchelli T; Molinelli E; Mazzanti S; Offidani A
    Dermatol Ther; 2021 Jan; 34(1):e14547. PubMed ID: 33190397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 induced telogen effluvium.
    Aksoy H; Yıldırım UM; Ergen P; Gürel MS
    Dermatol Ther; 2021 Nov; 34(6):e15175. PubMed ID: 34708909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red LED light therapy for telogen effluvium in the course of long COVID in patients with and without androgenetic alopecia.
    Gerkowicz A; Bartosińska J; Krakowski P; Karpiński R; Krasowska D; Raczkiewicz D; Kwasny M; Krasowska D
    Ann Agric Environ Med; 2024 Jun; 31(2):239-247. PubMed ID: 38940108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium?
    Koç Yıldırım S; Erbağcı E; Demirel Öğüt N
    J Cosmet Dermatol; 2022 May; 21(5):1809-1815. PubMed ID: 35201647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Review of the post-COVID-19 syndrome associated to acute telogen effluvium].
    Chávez-Chavira G
    Rev Med Inst Mex Seguro Soc; 2023 Jul; 61(4):496-501. PubMed ID: 37540705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hair and nail manifestations of COVID-19.
    Tammaro A; Adebanjo GAR; Parisella FR; Luzi F; Scarabello A
    J Cosmet Dermatol; 2022 Apr; 21(4):1339-1346. PubMed ID: 35032337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral minoxidil use in androgenetic alopecia and telogen effluvium.
    Feaster B; Onamusi T; Cooley JE; McMichael AJ
    Arch Dermatol Res; 2023 Mar; 315(2):201-205. PubMed ID: 35244759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation.
    Hussain N; Agarwala P; Iqbal K; Omar HMS; Jangid G; Patel V; Rathore SS; Kumari C; Velasquez-Botero F; López GAB; Vishwakarma Y; Nipu AP; Ahmed NK
    J Med Virol; 2022 Apr; 94(4):1391-1401. PubMed ID: 34931698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of hair loss in COVID-19 patients in Thailand.
    Triwongwaranat D; Thanomkitti K; Korviriyakamol T; Saengthong-Aram P; Varothai S; Thuangtong R
    Medicine (Baltimore); 2023 Dec; 102(49):e36539. PubMed ID: 38065902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minoxidil: a comprehensive review.
    Gupta AK; Talukder M; Venkataraman M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1896-1906. PubMed ID: 34159872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of SARS-CoV-2 infection and its vaccines in various types of hair loss.
    Aryanian Z; Balighi K; Hatami P; Afshar ZM; Mohandesi NA
    Dermatol Ther; 2022 Jun; 35(6):e15433. PubMed ID: 35266262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety.
    Russo PM; Fino E; Mancini C; Mazzetti M; Starace M; Piraccini BM
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):608-611. PubMed ID: 30394586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral minoxidil treatment for hair loss: A review of efficacy and safety.
    Randolph M; Tosti A
    J Am Acad Dermatol; 2021 Mar; 84(3):737-746. PubMed ID: 32622136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-COVID Telogen Effluvium.
    Tešanović Perković D; Vukojević M; Bukvić Mokos Z
    Acta Dermatovenerol Croat; 2022 Dec; 30(4):220-226. PubMed ID: 36919388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies.
    Gentile P
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
    Villani A; Fabbrocini G; Ocampo-Candiani J; Ruggiero A; Ocampo-Garza SS
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1485-1492. PubMed ID: 33660357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telogen effluvium and COVID-19: a cross-sectional study.
    Aldahish A; Vasudevan R; Salem H; Alqahtani A; AlQasim S; Alqhatani A; Al Shahrani M; Al Mohsen L; Hajla M; Calina D; Sharifi-Rad J
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7823-7830. PubMed ID: 37667959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.